New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies-Reference-Cited by-同舟云学术

New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies

Published:2007-08-01 Issue:8 Volume:12 Page:952-959
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Dellapasqua Silvia¹,Colleoni Marco¹,Castiglione Monica²,Goldhirsch Aron¹³

Affiliation:

1. a Medical Senology Research Unit & Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy

2. b International Breast Cancer Study Group (IBCSG) Coordinating Center, Bern, Switzerland

3. c Oncology Institute of Southern Switzerland, Bellinzona & Lugano, Switzerland

Abstract

Learning Objectives After completing this course, the reader will be able to: List the factors that should be considered when choosing the appropriate adjuvant treatment for an elderly women with operable breast cancer.Discuss the possible explanations that account for the underrepresentation of elderly patients in breast cancer clinical trials.Describe the clinical trials that are being specifically conducted in elderly patients with early breast cancer to evaluate different forms of adjuvant treatments. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-8-952

Reference42 articles.

1. Breast cancer screening;Sirovich;Surg Clin North Am,1999

2. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV;Crivellari;J Clin Oncol,2003

3. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial;Coombes;Lancet,2007

4. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17;Goss;J Natl Cancer Inst,2005

5. National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17;Goss;J Clin Oncol,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer in the oldest old (≥ 89 years): Tumor characteristics, treatment choices, clinical outcomes and literature review;European Journal of Surgical Oncology;2021-04

2. Adjuvant Treatment of Early Breast Cancer in the Elderly;Medicinal Chemistry;2016-03-31

3. Portrait, treatment choices and management of breast cancer in nonagenarians: An ongoing challenge;The Breast;2014-06

4. Contralateral prophylactic mastectomy in an Asian population: A single institution review;The Breast;2014-02

5. The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population;Oncology;2014